Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

High Resolution Gastric Mapping and Gastroduodenal Manometry

NCT: NCT06941545 · RECRUITING

NCT IDNCT06941545
StatusRECRUITING
Start Date2025-07-11
Completion2026-12-31
SponsorMayo Clinic (OTHER)
First posted
Last updated

Brief Summary

Dyspepsia is a common problem attributed to gastric sensorimotor dysfunctions ie, delayed, or less frequently rapid gastric emptying (GE), impaired gastric accommodation, and increased gastric sensation. Therapeutic options manage symptoms, and there is no FDA approved medical therapy for dyspepsia. There is a need for better objective understanding of sensorimotor dysfunction in dyspepsia, as well as noninvasive, efficacious, safe, and inexpensive treatments for dyspepsia. The purpose of this research is to identify disturbances and characterize phenotypes in patients with functional dyspepsia, and to assess the correlations between symptoms (during the manometry and in daily life), gastric emptying, electrical activity (BSGM), and pressure activity (manometry).

Frequently Asked Questions

What is High Resolution Gastric Mapping and Gastroduodenal Manometry?

High Resolution Gastric Mapping and Gastroduodenal Manometry is a clinical trial registered under NCT06941545. Current status: RECRUITING.

What is the status of NCT06941545?

The current status of NCT06941545 (High Resolution Gastric Mapping and Gastroduodenal Manometry) is: RECRUITING.

When did High Resolution Gastric Mapping and Gastroduodenal Manometry start?

High Resolution Gastric Mapping and Gastroduodenal Manometry started on 2025-07-11.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.